These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Etiology and prognosis of fulminant hepatitis and late-onset hepatic failure in Japan: Summary of the annual nationwide survey between 2004 and 2009. Oketani M; Ido A; Nakayama N; Takikawa Y; Naiki T; Yamagishi Y; Ichida T; Mochida S; Onishi S; Tsubouchi H; Hepatol Res; 2013 Feb; 43(2):97-105. PubMed ID: 23409848 [TBL] [Abstract][Full Text] [Related]
12. Hepatitis B virus sequence changes evolving in liver transplant recipients with fulminant hepatitis. Sterneck M; Günther S; Gerlach J; Naoumov NV; Santantonio T; Fischer L; Rogiers X; Greten H; Williams R; Will H J Hepatol; 1997 Apr; 26(4):754-64. PubMed ID: 9126786 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and effectiveness of anti-HBV therapy with early withdrawal of HBIG prophylaxis to prevent HBV recurrence following liver transplantation. Ku W; Wang U; Nguyen MH Expert Opin Biol Ther; 2015 May; 15(5):665-77. PubMed ID: 25865452 [TBL] [Abstract][Full Text] [Related]
14. Lamivudine or adefovir dipivoxil alone or combined with immunoglobulin for preventing hepatitis B recurrence after liver transplantation. Katz LH; Tur-Kaspa R; Guy DG; Paul M Cochrane Database Syst Rev; 2010 Jul; (7):CD006005. PubMed ID: 20614442 [TBL] [Abstract][Full Text] [Related]
15. Prophylactic antiviral therapy in allogeneic hematopoietic stem cell transplantation in hepatitis B virus patients. Liao YP; Jiang JL; Zou WY; Xu DR; Li J World J Gastroenterol; 2015 Apr; 21(14):4284-92. PubMed ID: 25892880 [TBL] [Abstract][Full Text] [Related]
16. Clinical epidemiology of fulminant hepatitis in Japan before the substantial introduction of liver transplantation: an analysis of 1309 cases in a 15-year national survey. Sato S; Suzuki K; Takikawa Y; Endo R; Omata M; Hepatol Res; 2004 Nov; 30(3):155-161. PubMed ID: 15588781 [TBL] [Abstract][Full Text] [Related]
17. Liver transplantation for hepatitis B-induced liver disease: long-term outcome and effectiveness of antiviral therapy for prevention of recurrent hepatitis B infection. Perrakis A; Förtsch T; Del Medico A; Croner RS; Vassos N; Yedibela S; Lohmüller C; Zopf S; Hohenberger W; Müller V Transplant Proc; 2013 Jun; 45(5):1953-6. PubMed ID: 23769081 [TBL] [Abstract][Full Text] [Related]
18. Case-control study for the identification of virological factors associated with fulminant hepatitis B. Kusakabe A; Tanaka Y; Mochida S; Nakayama N; Inoue K; Sata M; Isoda N; Kang JH; Sumino Y; Yatsuhashi H; Takikawa Y; Kaneko S; Yamada G; Karino Y; Tanaka E; Kato J; Sakaida I; Izumi N; Sugauchi F; Nojiri S; Joh T; Miyakawa Y; Mizokami M Hepatol Res; 2009 Jul; 39(7):648-56. PubMed ID: 19456899 [TBL] [Abstract][Full Text] [Related]
19. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Gane EJ; Patterson S; Strasser SI; McCaughan GW; Angus PW Liver Transpl; 2013 Mar; 19(3):268-74. PubMed ID: 23447403 [TBL] [Abstract][Full Text] [Related]
20. Fulminant hepatitis B virus: recurrence after liver transplantation in two patients also infected with hepatitis delta virus. Marsman WA; Wiesner RH; Batts KP; Poterucha JJ; Porayko MK; Niesters HG; Zondervan PE; Krom RA Hepatology; 1997 Feb; 25(2):434-8. PubMed ID: 9021960 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]